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Abstract:  Infection with Human immunodeficiency virus type-1 (HIV-1) induces severe alterations of the immune 
system leading to an increased susceptibility to opportunistic infections and malignancies. However, exposure to the virus 
does not always results in infection. Indeed, there exist individuals who have been repeatedly exposed to HIV-1 but do not 
exhibit clinical or serological evidence of infection, known as exposed seronegative individuals. Many studies have 
focused on the different mechanisms involved in natural resistance to HIV-1 infection, and have reported several factors 
associated with this phenomenon, including the presence of genetic polymorphisms in the viral coreceptors, innate and 
adaptive immune cells with particular phenotypic and functional features, and molecules such as antibodies and soluble 
factors that play an important role in defense against infection by HIV-1. The study of these factors could be the key for 
controlling this viral infection. This review summarizes the main mechanisms involved in resistance to HIV-1 infection. 
Keywords:  HIV-1 (Human immunodeficiency virus type-1), natural resistance, exposed seronegative individuals, 
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INTRODUCTION 
  Human immunodeficiency virus type-1 (HIV-1) infection 
remains one of the main public health problems in the world 
for which a vaccine is not yet available. In 2008 around 33.4 
million persons were infected with HIV-1 throughout the 
world, with an annual incidence of 2.7 million infections, of 
which approximately 50% correspond to infections in 
women [1]. 
  The natural history and development of HIV-1 infection 
is heterogeneous, if one considers the variability in the 
acquired immunodeficiency syndrome (AIDS)-free period 
exhibited by infected individuals; the median time of 
appearance of AIDS clinical symptoms is between 8 and 10 
years after infection. However, cohort studies have identified 
a small fraction of seropositive (SPs) individuals, about 5–
10%, who despite infection for more than 10 years, remain 
symptomless and maintain a relatively high CD4+ cell count 
(>500 CD4+ cells/l) without antiviral therapy; they are 
known as long-term non-progressors (LTNPs) [2]. In 
addition, there are two new phenotypes of SP individuals 
who exhibit a spontaneous and sustained control of viral 
replication at least for one year in the absence of 
antiretroviral therapy; the first group is known as elite 
controllers since they maintain undetectable HIV RNA 
levels (< 50 copies/mL), and the second group known as 
viremic controllers maintains detectable viral loads although 
< 2000 copies/mL [3]. Likewise, individuals have been 
reported, who are frequently exposed to the virus by sexual, 
parenteral or vertical routes, but do not exhibit serological 
evidence of infection, or any signs or symptoms of 
immunodeficiency; they are known as high-risk exposed   
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HIV-seronegative or exposed uninfected (ESNs) individuals 
[2]. These groups have revealed the existence of natural 
resistance mechanisms against HIV. Several studies have 
been aimed at determining the various mechanisms involved 
in natural resistance to HIV infection, and so far it has been 
associated with immunological factors, host genetic variants 
as well as soluble factors that prevent or limit viral infection 
(Fig. (1) and Table 1). Among the genetic factors, the CCR5-
delta 32 (CCR5-32) mutation has been the most widely 
investigated and is associated with natural resistance to HIV 
infection, because it efficiently inhibits entry of R5 strains; 
some treatments against HIV infection have even been 
developed based on these findings. In addition, other single 
nucleotide polymorphisms (SNPs) in HIV coreceptors and 
their natural ligands are involved in this process [4]. 
  Several investigators have demonstrated the presence of 
immunological mechanisms that can reduce the risk of 
acquiring HIV infection or limit its progression. Certain 
reports indicate that apoptosis of target cells [5], increased 
production of interferon gamma (IFN-) by natural killer 
(NK) cells [6] and positive regulation of costimulatory 
molecules [7] are factors associated with resistance. The 
humoral response contributes significantly to resistance to 
HIV infection through the production of anti- HIV IgA in 
mucosal [8] and finally, several soluble factors such as 
RNases, chemokines, cytokines and cationic proteins are 
involved in blocking HIV infection in ESNs or in decreasing 
the time required to disease progression in LTNPs 
individuals [9]. 
  In this review, we describe the main factors involved in 
natural resistance to HIV-1 infection associated with ESN 
individuals, including some findings of our research group. 
ESNs GENETIC CHARACTERISTICS 
  The differences in the susceptibility to HIV-1 infection 
are due partly to genetic characteristics, and many studies are 36    The Open Virology Journal, 2011, Volume 5  Taborda-Vanegas et al. 
aimed at identifying and establishing the relationship 
between the presentation of different polymorphisms and the 
lack of infection or delay in AIDS progression. The main 
genetic conditions are described. 
Polymorphisms in Chemokine Receptors 
  The most important genetic factor related to natural 
resistance to HIV-1 infection is the presence of the 32 
mutation in the CCR5 gene. This mutation occurs in 
approximately 10% of Caucasian individuals and represents 
a deletion of 32 bp resulting in the synthesis of a truncated 
protein with only 4 of the 7 transmembrane domains 
required for protein expression at the cell surface [10]. 
Homozygote individuals for this mutation (32/32) are 
highly resistant to HIV-1 infection [10], mainly to R5 
strains, whereas the heterozygotes are susceptible to 
infection, but exhibit slow progression to AIDS [10]. 
Nevertheless, this mutation only explains 3.6% of ESNs 
[11], suggesting that other mechanisms are involved in 
natural resistance to infection. 
  Different polymorphisms in the CCR5 promoter region 
have been reported and associated with different rates of 
AIDS progression and natural resistance to HIV infection 
[12]. Many mutations have been described in this gene, 
which can produce amino acid substitutions and alter the 
function of the coreceptor [13]. The polymorphism -2459 
(A/G) in the CCR5 promoter has been associated with 
delayed progression to AIDS, and seropositive individuals 
with the G/G genotype display slower progression to AIDS 
 
Fig. (1). Mechanisms of resistance involved in the protection against HIV-1-infection and AIDS-progression. Target cells have 
polymorphisms in CCR5 gene or other alternative viral coreceptors, such as CCR2 (1), all of them induce low or non-expression of these 
coreceptors, inhibiting viral entry. This step can be also blocked by high production of the coreceptors ligands, MIP-1/, RANTES and 
SDF-1 (2). Elevated spontaneous and inducible apoptosis of monocytes and other HIV-1-target cells has been reported in ESNs (3). 
Increased release of soluble antiviral factors APOBEC3G, CAF,  and - defensins, type I IFN, LIF, MIP-1/, RANTES, RNases, SDF-1, 
SLPI, TRIM5 and elafin block viral entry or replication (4). ESNs individuals exhibit high activity in NK cells and DCs. NK cells express 
KIR3DS1 and KIR3DL1 related to cell activation (5) and are able to produce IFN- (6). DCs also express the co-stimulatory molecules 
CD80 and CD86 (7) and produce IFN- (6). Type I IFN induces HLA expression, apoptosis of infected cells, production of antiviral 
molecules, and block viral replication. The specific immune response is characterized by the presence of CTLs restricted to HLA-B57 and –
B27, presenting immunodominant peptides (8), production of cytokines such as RANTES, MIP-1, IL-6, IFN-, TNF- and  and IL-2 that 
increase the immune response and expression of markers associated with T cell activation (9). B-cells produce neutralizing IgA antibodies, 
detectable in serum, mucosa and breast milk (10). Natural Resistance to HIV-1 Infection  The Open Virology Journal, 2011, Volume 5    37 
than those with the A/A genotype [14]. The CCR5-32 allele 
together with the CCR5 -2459G SNP have been associated 
with a negative effect on the expression of CCR5 in both T-
helper cells and monocytes from ESNs, indicating the 
relationship of these genotypes with natural resistance to 
HIV infection [12]. 
 Previously,  Mummidi  et al. reported high genetic 
variation in the sequence of the CCR5 regulatory region in 
humans and these CCR5 haplotypes were classified in seven 
evolutionarily distinct human haplogroups (HH): HH-A, -B, 
-C, -D, -E, -F, and –G; thus, each haplogroup included the 
combination of a unique SNP in the CCR5 regulatory region, 
and the presence of either the CCR2 I64V SNP or CCR5-
32 mutation [15]. The HH-G2 which includes the CCR5-
32 mutation was reported to be protective in children 
exposed to HIV during prgnancy [16]. The HH-A and HH-
F2 haplotypes are significantly more frequent in African 
Americans than in Caucasians, and their presence is 
associated with disease retardation in SP individuals; in 
addition, the genotype HH-C/HH-G2 is related with the 
strongest protective effects in the same population [17]. 
Recently, it was observed that the frequency of the HH-
C/HH-G1 and HH-C/HH-F2 genotypes is higher in ESNs 
compared to SPs, indicating that these haplogroups could be 
associated to HIV resistance (J. Vega, unpublished 
observations, 2009). 
  In HIV-1-exposed but seronegative intravascular drug 
users (IDUs) of southeast Asia but not in HIV-1 infected 
individuals, a guanine to adenine substitution in the 316 
position of the CCR5 gene (CCR5 G316A) has been 
reported; it affects the cellular expression of the coreceptor, 
suggesting its association with natural resistance to infection 
[18]. 
 In  vitro studies have demonstrated that HIV-1 can use 
alternative coreceptors, which can exhibit allelic variations 
that have been associated with resistance to infection and 
delay in AIDS progression. Among the polymorphisms 
described in these coreceptors, a genetic variant in the 
coding region of the CCR2 (CCR2-V64I) produces a change 
from valine to isoleucine in position 64 of the protein. Some 
studies have suggested that the CCR2-V64I polymorphism 
induces negative expression of the CCR5 and CXCR4 
molecules at the cell surface, decreasing the availability of 
susceptible cells to HIV-1 infection [19]. 
  It is known that CCR2 and CCR5 loci are in close 
proximity, about 10 kb, on chromosome 3, opening the 
possibility to find non-random association of their alleles. 
Smith et al., have shown that the mutant allele CCR2-64I is 
in strong linkage disequilibrium with the CCR5-32 allele in 
Afro-Americans, Hispanics and Asian individuals [20]. In 
addition, several reports indicate that the CCR2-64I allele 
and the polymorphism CCR5-59653T in the CCR5 promoter 
are in linkage disequilibrium [21, 22]. The demonstration 
that these mutant alleles are protective against HIV-1 
infection and AIDS progression has important implications 
for therapy, since these receptors are required for viral entry. 
Polymorphisms in Soluble Factors 
  The macrophage inflammatory protein-1 alpha (MIP-
1/CCL3) and beta (MIP-1/CCL4) and the regulated on 
activation, normal T-cell expressed and secreted 
(RANTES/CCL5) are CCR5 ligands; several studies have 
demonstrated the antiviral activity of these proteins [4]. The 
MIP-1 and MIP-1 monokines have two genetic variants, 
CCL3L1  and  CCL4L1, respectively; they encode proteins 
that also bind to CCR5, increasing ligand availability, 
competing with the virus for the coreceptor and inhibiting 
HIV-1 infection [4]. These genetic variants decrease the 
probability of acquiring HIV-1 infection and promote 
recovery of the CD4+ cells after initiation of Highly active 
antiretroviral treatment (HAART), particularly in individuals 
with high copy numbers of these alleles, suggesting that 
lower availability of CCR5 on the cell surface could reduce 
HIV binding, affecting HIV infection [4]. Recently, a C459T 
SNP in the intron 1 of MIP-1 was described whose 
frequency was higher in ESNs compared to SPs, suggesting 
that it could increase the efficiency of mRNA processing, 
thus increasing protein expression (J. Vega, unpublished 
observations, 2009). 
  Some polymorphisms in RANTES are associated to 
resistance. Liu et al. reported that -28G and -403G/A SNPs 
in the upstream non-coding region are associated with 
increased transcription of the RANTES gene, leading to 
Table 1.  Protective Factors Associated to Different Routes of HIV-1 Transmission 
 
Protective Factor  Nature of Factor  Type of Transmission Involved 
Delta 32 Mutation  Genetic  Sexual and parenteral transmission of R5 strains 
Other polymorphisms in HIV-1 coreceptors  Genetic  Sexual, vertical and parenteral 
SNPs in RANTES, MIP-1/ and DEFB1 genes  Genetic  Sexual and vertical 
HLA alleles   Genetic  Vertical and sexual 
High frequency of KIR3DL1, KIR2DL2 and KIR2DL5  Genetic  Sexual 
Apoptosis of monocytes  Innate immune response  Sexual 
Production of cytokines by NK cells  Innate immune response  Sexual and parenteral 
Activity and phenotype of DC  Innate immune response  Vertical 
Soluble proteins: APOBEC3G, CAF, defensins, IFNs, LIF, MIP-
1/, RANTES, RNases, SDF-1, SLPI and TRIM-5 
Innate immune response  Sexual and vertical 
Production of specific IgA  Humoral immune response  Sexual and vertical 38    The Open Virology Journal, 2011, Volume 5  Taborda-Vanegas et al. 
reduced CD4+ T lymphocyte depletion in HAART naive 
HIV-1-infected individuals [23]. 
  Polymorphisms in human beta defensins (HBD) have 
been associated with resistance to HIV-1 infection. We 
reported that the homozygosity for the A692G polymor-
phism in DEFB1 was significantly more frequent in ESNs 
than in SPs [24]. 
Major Histocompatibility Complex (MHC) Alleles 
  Alleles of the MHC involved in slow progression to 
AIDS and resistance to HIV infection have been reported. 
HLA-B57-restricted CTLs target several gag epitopes that 
induce much better HIV immune responses through cytolytic 
destruction of infected cells. HLA-B27 has been associated 
with delayed HIV-1 escape due to broad reactivity against 
gag epitopes [25]. Both alleles occur at a higher frequency in 
LTNPs compared to healthy controls (HCs), suggesting that 
these molecules have an important antiviral role. 
  The role of the HLA in HIV-1 vertical transmission had 
been also explored. An increasing class I HLA concordance 
between mother/neonate was associated to a higher risk for 
HIV-1 transmission, that was gene-dose related, suggesting 
that mother-child MHC discordance could be a protective 
factor through-out the allogenic immune response. As will 
be discussed later, and consistent with this hypothesis, we 
observed that mother/neonate HLA discordance is associated 
with high mRNA expression of RNase 1 and with the 
production of an alloantigen-stimulated factor (ASF), a 
soluble protein with strong anti-HIV-1 activity [26]. 
IMMUNE RESPONSE DURING HIV-1 EXPOSURE 
Innate Response 
  Several investigations have centered on the character-
istics of the innate immune response in ESNs, considering 
that innate immunity is very active on mucosal surfaces that 
are primary sites of HIV-1 entry. 
  Apoptosis has been reported not only as a pathogenic 
mechanism, but also as a mechanism of resistance and 
control of a variety of infections. We recently determined the 
role of apoptosis in natural resistance to HIV infection. We 
found that peripheral blood monocytes in the ESNs group 
had a greater predisposition to undergo spontaneous 
apoptosis as well as apoptosis induced by HIV infection in 
vitro, compared to monocytes from HCs at low risk of HIV 
infection. This suggests that monocytes could play an 
important role in the control of HIV infection by undergoing 
apoptosis [5]. 
  During HIV-1 infection the function and number of NK 
cells is altered; however, NK cells secrete soluble factors 
that inhibit HIV infection in vitro. We reported that the 
expression of IFN- by phorbol-12-myristate-13-acetate 
(PMA)/Ionomycin-activated CD56
bright NK cells and 
CD3+/CD56+ cells was significantly higher in ESNs 
compared to HCs. Since anti-viral effects of IFN- are well 
established, our results suggest that IFN- production by 
innate immune cells might be one of the multiple factors 
involved in controlling the establishment of sexually 
transmitted HIV-1 infection [6]. Scott-Algara et al. evaluated 
the lytic activity of NK cells in IDUs, who remained HIV-1 
uninfected despite high-risk exposure: there was a higher 
lytic activity in ESNs than in controls or seroconverters. In 
addition, NK cells producing IFN-, Tumor necrosis factor-
alpha (TNF-) and the chemokines CCL3, CCL4, and CCL5 
were also higher among ESNs [27]. Boulet et al. demons-
trated an increased proportion of KIR (Killer immuno-
globulin-like receptor)-3DS1 homozygotes in ESNs compared 
to HIV-1 infected individuals. This finding was associated to an 
increase in NK cell activation, induction of a strong anti-HIV-1 
response and inhibition of the establishment of infection [28], 
supporting the anti-HIV-1 activity of NK cells. 
  Dendritic cells (DCs) play a critical role by providing the 
signals required to induce immune responses. We therefore 
evaluated the number, phenotype and function of DCs during 
intrauterine exposure to HIV-1 in uninfected babies born to 
HIV-1 positive mothers. Intrauterine exposure of the DCs to 
HIV-1 induces qualitative and quantitative changes in these 
cells, such as positive regulation of CD80 and CD86 in 
response to several stimuli, suggesting that these cells could 
be involved in increasing T lymphocyte activation in these 
children and could be responsible for the protective immune 
response observed [7]. 
Innate Soluble Factors with anti-HIV-1 Activity 
  A significant number of soluble factors produced by 
several cell types have been reported with the capacity to 
inhibit HIV-1 replication at different steps of the virus life 
cycle, without eliminating infected cells and through 
enhancement of specific anti-HIV-1 cellular mechanisms [9]. 
Among the soluble factors described, those with high levels 
of anti-HIV-1 activity are the -chemokines (RANTES, 
MIP-1 and MIP-) [29], -chemokines such as stromal cell-
derived factor-1 (SDF-1) [30], the CD8+ cell antiviral factor 
(CAF) [31], IFN, ribonucleases (RNases) associated with 
human chorionic gonadotropin [32], ASF [26], the secretory 
leukocyte protease inhibitor (SLPI) [33], the recently studied 
apolipoprotein B mRNA-editing enzyme-catalytic polypep-
tide-like 3G (APOBEC3G) [34], and the  and  human 
defensins [35, 36]. 
Chemokines 
  The RANTES (CCL5), MIP-1 (CCL3), and MIP-1 
(CCL4) chemokines are produced by macrophages, NK 
cells,  T lymphocyte and T CD8+ lymphocytes [9]. The 
antiviral role of these chemokines is exerted by competition 
with the virus for cell adhesion, because they are natural 
CCR5 ligands, and their affinity also induces coreceptor 
internalization in early endosomes [29]. The levels of 
RANTES and MIP-1 are elevated in cultures of HIV-1 env-
specific CD4+ T cells from ESNs compared to HCs; in 
addition, these chemokines were capable of inhibiting 
replication of macrophage-tropic HIV-1 strains [29]. 
Additionally, Paxton et al. reported that CD4+ T cells of 
ESNs are less susceptible to infection and this was 
associated with the activity of RANTES, MIP-1, and MIP-
1 in these cells [37]. 
 The  -chemokine SDF-1 is the natural ligand for 
CXCR4, which is the X4 HIV-1 strain coreceptor. This 
factor is secreted by bone marrow stromal cells, epithelial 
cells, monocytes and naïve T lymphocytes [9]. Studies 
performed  in vitro have demonstrated that SDF-1 binds 
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membranes by inducing internalization and lysosomal 
degradation, decreasing cell susceptibility to infection by X4 
HIV-1 strains [30]. 
Interferons 
  Type I IFN inhibits HIV-1 cell adhesion and induces 
expression of anti-HIV-1 proteins, such as RNase-L. 
Moreover, IFN- induces apoptosis of HIV-1-infected CD4+ 
T lymphocytes and inhibits viral replication, diminishing the 
production of infectious viral particles. In addition, a higher 
expression of IFN- was reported in uninfected commercial 
sex workers with high risk of HIV infection compared to 
controls, supporting the role of this cytokine in the protection 
of sexual HIV-1 transmission [38]. 
  ESN NK cells produce greater amounts of IFN- 
compared to cells from HCs and the mRNA levels of this 
cytokine are higher in PBMCs and genital mucosa biopsies 
of ESNs compared to HCs, suggesting its association to 
resistance considering that IFN- inhibits HIV-1 
transcription [6]. In addition, Kuhn et al. reported that in 
sanguineous umbilical cord cells of uninfected children born 
to HIV-1 positive mothers, the IFN- concentration is 
increased, suggesting that this cytokine plays an important 
role in protection from vertical transmission of HIV [39]. 
Ribonucleases 
  RNases are regulatory enzymes that control several cell 
processes from alternative RNA splicing to organogenesis, 
and their therapeutic potential has been suggested and 
investigated in infectious diseases and cancer. We previously 
reported that the functional activity of ASF is resistant to 
high temperature (>90ºC), decreased by RNase inhibitors 
and inhibited by an antibody against eosinophil-derived 
neurotoxin (EDN), suggesting that the majority of the anti-
HIV-1 activity of ASF is due to EDN or a closely related 
RNase [32]. We recently reported that recombinant RNase 
A, EDN and angiogenin inhibit primary HIV-1 infection of T 
cell blasts, suggesting that naturally-occurring RNases play a 
role in host resistance to HIV-1 and other viral infections 
[40]. Additionally, we evaluated if maternal-fetal alloantigen 
stimulation is associated with ASF production and/or 
placental mRNA expression of three RNases: EDN, RNase 1 
and angiogenin. We found that mother/neonate HLA 
discordance at the A and B loci associates with mRNA 
expression of placental RNases, particularly RNase 1, and 
with the production of ASF in vitro; these results are 
consistent with the hypothesis that maternal-fetal HLA 
differences are important in preventing vertical transmission 
of certain infectious pathogens, including HIV-1 [26]. 
Defensins 
  Defensins are cysteine-rich cationic peptides with 
antimicrobial activity against a broad spectrum of 
microorganisms; they are divided into three groups based on 
their structure: ,  and  (the latter only found in nonhuman 
primates) [35]. Human beta defensins (HBD) are found 
primarily in mucosa, the main ports of HIV entry. In 
humans, six HBDs have been reported; HBD-1 is 
constitutively expressed, whereas HBD-2 and -3 are induced 
by viral or bacterial products and by cytokines such as IL-1-
 and TNF- [41]. HBD-2 and -3 mRNAs are induced by 
HIV-1 in human oral epithelial cells, without infecting the 
cells. HBD-2 and -3, but not HBD-1, exhibit strong dose 
dependent anti-HIV-1 activity, mainly on X4 strains; the 
inhibition occurs through binding to virions with permanent 
effect on viral infectivity and downregulation of the HIV-1 
coreceptor CXCR4 in PBMCs and T lymphocytes [42]. In 
addition, Sun et al. showed that both HBD-2 and -3 inhibit 
infections by R5 and X4 HIV-1 strains in PBMCs. This 
study also demonstrated that HBD-2 had a direct effect on 
viral particles in a dose-dependent manner at doses similar to 
those found in the oral cavity (100 g/ml) and these 
defensins inhibited accumulation of early products of reverse 
transcription [35]. 
  Recently, we observed an increased number of copies of 
HBD-1, -2 and -3 mRNA in vaginal and endocervical 
mucosa from ESNs compared to HCs, although these 
differences were not statistically significant. In addition, a 
significantly higher expression of HBD-2 and -3 mRNAs 
was observed in oral mucosa from ESNs compared to the 
levels in HCs, supporting the role of HBDs during oral 
exposure to HIV-1 [24]. Thus, the increased HBD expression 
exhibited by ESNs compared to HCs might reflect a genetic 
trait associated with resistance to HIV-1 infection. 
  So far, six human -defensins have been described (HD-1 
to -6), playing an important role in innate immunity. HNP-1 
to -4 are abundant in polymorphonuclear leukocytes [43], 
while HD-5 and -6 are produced predominantly by intestinal 
Paneth cells. HNP-1 to -3 inhibit replication of R5 and X4 
HIV-1 strains, including several primary isolates [36]. Chang 
et al. showed that recombinant HNP-1 inhibited HIV-1 
infection in the absence of serum by direct effect on the viral 
particle. In contrast, in presence of serum the effect is on the 
cell, affecting steps prior to transcription and nuclear import; 
likewise, interference with protein kinase C (PKC) signaling 
in primary CD4+ T cells by HNP-1 appears to be associated 
with its inhibitory effect, considering that PKC upregulates 
HIV transcription through NF-B activation and MAPK 
signaling pathways [44]. 
  It has been reported that CD8+ T cells and cervical-
vaginal mononuclear cells from ESNs produced 10-fold 
higher amounts of HNP compared to HCs, and the levels of 
HNP mRNA and HNP-expressing cells were increased in 
cervical biopsies of ESNs compared to HCs, suggesting the 
role of these components in the protective immune response 
that characterizes ESNs [45]. Supporting their role in natural 
resistance to HIV infection, Kuhn et al., reported increased 
levels of HNP-1 to -3 in maternal milk from HIV-1 positive 
mothers who did not transmit the virus to their infants, 
compared to transmitting women, suggesting that these 
proteins are important in inhibiting viral postnatal 
transmission, probably inactivating viral particles [46]. In 
addition, immature monocyte-derived DCs from elite and 
viremic controllers produced higher amounts of HNP-1 to -3 
compared to HCs; thus high production of HD-1 to -3 by 
immature DCs appears to be also a host factor limiting HIV-
1 replication [47]. 
Other Soluble Factors 
 CAF: It is a soluble factor produced by CD8+ T cells 
with non-cytotoxic anti-HIV activity by blocking viral 
transcription [31]. To date, no CD8 T cell-secreted cytokine, 
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identify with the hallmarks that defines the suppressing HIV-
1 activity of CAF [48]. Stranford et al. reported that CD8+ T 
cells inhibit HIV replication in acutely infected CD4+ T cells 
of ESNs and this response efficiently inhibited HIV infection 
in PBMCs, suggesting that antiviral soluble factors with non-
cytotoxic activity could be contributing to HIV resistance in 
this population [49]. In addition, Mackewitz et al., reported 
that HIV-1 asymptomatic individuals exhibited the highest 
CAF activity compared to symptomatic and AIDS patients 
suggesting that CAF could be influencing AIDS progression 
[50]. 
 SLPI: it is a soluble component of saliva, which is 
secreted primarily by epithelial cells lining mucosal surfaces 
and skin, neutrophils, and by lipopolysaccharide-stimulated 
macrophages [9]. Higher salivary SLPI levels were 
associated with a decreased risk of HIV-1 infection among 
infants who were exposed to HIV-1 via breast-feeding after 
the first month [51]. In agreement with this, in a study 
carried out by Pillay et al., the SLPI levels in vaginal fluid 
samples of HIV-1 positive women whose babies became 
infected were lower than in samples from non-transmitting 
women [52], implying that SLPI could protect against 
vertical transmission of HIV-1. 
 TRIM5: Tripartite motif (TRIM) proteins constitute a 
family of proteins that share a conserved tripartite 
architecture [53]. TRIM5 is the only member of these 
intracellular factors involved in the inhibition of HIV-1 
replication. The rhesus monkey TRIM5 (TRIM5rh) 
recognizes the incoming HIV-1 core and promotes its 
premature disassembly or degradation before reverse 
transcription [54]. Human TRIM5 has a weak capsid-
binding capability compared to TRIM5rh, exhibiting 
reduced anti-HIV activity; however, it has been postulated 
that a single amino acid substitution could increase its ability 
to inhibit HIV-1 replication [55]. Therefore, polymorphisms 
within TRIM5a might affect susceptibility to HIV-1 
infection. Javanbakht et al., reported a higher frequency of 
the allele TRIM5 136Q in ESN compared to HIV-1 
infected individuals, suggesting a possible protective role of 
this variant. In fact, TRIM5 136Q protein showed higher 
anti-HIV-1 activity in vitro than TRIM5 R136 protein 
supporting its protective effect [56]. 
 Trappin-2: This factor is a protease inhibitor produced at 
mucosal surfaces by epithelial cells and possibly 
macrophages, in secreted and active forms known as elaﬁn. 
Elafin is an antimicrobial and antiinﬂammatory molecule, 
which inhibits neutrophil elastase and proteinase 3 [57]. 
Gosh et al., demonstrated that recombinant Trappin-2/Elafin 
inhibits both X4/T-tropic IIIB and R5/M-tropic BaL HIV-1 
in a dose-dependent manner [58]. In addition, Iqbal et al., 
using proteomics approach identified high levels of elafin in 
genital secretions from HIV-resistant women, suggesting its 
protective role during HIV-1 exposure [59]. 
 APOBEC3G:  this enzyme is a protein with cytidine 
deaminase activity that limits HIV-1 replication. The 
mechanism involved in this activity is excessive deamination 
of cytidine to uridine in minus strand reverse transcripts, a 
process resulting in guanosine to adenosine hypermutation of 
plus strand DNAs and in the impairment of proviral 
integration into the host genome [34]. In ESNs, an increasing 
level of APOBEC3G mRNA in PBMCs was observed 
compared to HCs; interestingly, the mRNA levels of 
APOBEC3G decreased a year after termination of exposure. 
These findings were associated with low susceptibility to 
HIV-1 infection in vitro [60]. 
Humoral Response 
  The humoral response is one of the most important 
mechanisms in HIV-1 resistance. Indeed, in some ESN 
individuals, resistance to infection has been associated to 
HIV-1 specific immunoglobulin A (IgA) production in 
cervicovaginal secretions, saliva, serum, maternal milk and 
urethral swabs [2]. Although the mechanisms involved in the 
production of these antibodies with high specificity and 
neutralizing capacity is not yet clearly defined, it has been 
postulated that during HIV-1 exposure some viral particles 
are processed and presented to T cells, enhancing specific 
humoral responses [2]. Clerici et al. demonstrated that ESNs 
IgA binds to a single epitope in the extracellular portion of 
gp41 (amino acidic residues 581-599: QARILAV). This 
epitope is involved in the gp41 - gp120 interaction and 
becomes accessible to speciﬁc IgA only after gp120 has 
bound the CD4 molecule in the target cell; most likely once 
the antibody binds gp41 the fusion of membranes is blocked. 
In contrast, IgA from SPs recognizes different epitopes in the 
gp120 and gp41 transmembrane region, suggesting that 
recognition of the QARILAV residues is important for 
resistance to HIV infection, and confirms that qualitative 
rather than quantitative differences between IgAs produced 
by ESNs and SPs are more relevant [61]. Supporting the 
protective role of humoral responses in HIV infection, 
Hirbord  et al., demonstrated an independent association 
between reduced HIV acquisition and the prior detection of 
both genital HIV-neutralizing IgA and HIV-speciﬁc cellular 
proliferation [62]. 
  Additionally, higher levels of specific HIV-1 gp160 IgA 
were found in saliva of HIV-1 negative children, born to 
HIV-1 positive mothers, who received maternal breast-
feeding, compared to HCs, suggesting that a specific IgA 
response in oral mucosa is important for inhibiting vertical 
transmission [63]. Considering that oral sex could be a risk 
factor for HIV-1 infection, Hasselrot et al. evaluated the IgA 
production in saliva of uninfected men that have oral sex 
without protection with SP individuals, and reported that this 
exposure is sufficient to induce IgA1-mediated HIV-
neutralizing response that can reduce the risk of infection 
[64]. CCL28 (also called mucosae-associated epithelial 
chemokine) is a recently described CC chemokine that binds 
CCR10 as well as CCR3 receptors, which are expressed by 
IgA-expressing plasma blasts and plasma cells [65]. CCL28 
is detected in trachea, colon, rectum, and exocrine glands 
such as salivary and mammary glands [66]. Thus, CCL28 is 
implicated in recruitment of these cells to the mucosal 
effectors sites. Castelletti et al., evaluated the CCL28 circuit 
in the context of HIV-1 infection, finding that CCL28 was 
augmented in breast milk, plasma and saliva of SP and ESN 
women. Likewise, they showed that CCR3+ and CCR10+ B 
lymphocytes were increased in these individuals. This 
suggests a role of CCL28 in the modulation of mucosal 
immunity in HIV exposure and infection [67]. 
  Despite of all the evidence supporting the role of humoral 
responses, particularly of IgA in blocking HIV-1 infection, Natural Resistance to HIV-1 Infection  The Open Virology Journal, 2011, Volume 5    41 
several reports, using various cohorts of ESN failed to show 
this association [68, 69]. In fact, Alexander et al., discussed 
the possibility that issues such as differences among the ESN 
cohorts evaluated, variation in processing samples, differen-
ces in the prevalence and frequency of unprotected HIV 
exposure and difficulties to obtain accurate measurements of 
specific antibody levels, among others, are responsible for 
the contradictory results. The recommendations to avoid bias 
in the investigations about IgA include the use of proper 
control groups and proper sample preparation in order to 
ensure that the intrinsic properties of the samples do not 
influence the results [70]. 
Cellular Response 
  Quantitative and qualitative differences in several 
effector mechanisms have been described in ESNs, 
suggesting that some of these parameters might be 
influenced by virus exposure and could be associated to 
resistance exhibited by these individuals. 
  HIV-1 specific CD4+ T cells and PBMCs from ESNs 
produce high levels of RANTES and MIP-1 [29] and 
mainly a Th1 cytokine pattern in response to viral peptides, 
compared to SP individuals [71]. Additionally, Biasin et al. 
reported significantly higher levels of mRNA for IL-6, IFN-
, and TNF- and  in cervical samples and PBMCs of ESNs 
compared to HCs [72]. Taken together, these results suggest 
that a Th1 response characterized by the high production of 
IL-2 and IFN-, and low levels of IL-10 could protect against 
HIV-1 infection. 
  Immune activation is essential to maintain effective 
immune responses against pathogens including HIV [72]; 
however, activation of infected cells induces viral 
replication. The involvement of immune activation in both, 
during a protective immune response against HIV and in 
promoting viral pathogenesis has been suggested by several 
studies in ESNs. In a Central African cohort, the number of 
HLA-DR+CD4+ T cells were found lower in ESNs than in 
HCs; in addition, in vitro infection of unstimulated PBMC 
was decreased in ESNs compared to HCs, indicating that low 
activation and susceptibility may contribute to HIV-1 
resistance [73]. 
  In contrast, most reports suggest that ESNs exhibit an 
immune activation profile. Biasin et al., reported that PBMC 
from ESNs express higher levels of IL–6, IL-10, IL-12, IFN-
 and TNF- and - mRNA; likewise CCR5 and CXCR4 
mRNA in cervical mucosa biopsy specimens and HIV-
speciﬁc IFN-–secreting CD8+ T lymphocytes in cervical 
vaginal washes were augmented in ESNs compared to HCs. 
In addition, they found that CD4+CD25+ and CD8+CD38+ 
T lymphocytes were significantly augmented in ESNs, 
compared to HCs [72]. Interestingly, the level of memory 
and activation was directly correlated to the viral load of 
their HIV-1–infected partners, whereas the level of naive and 
CD28+ T cells was inversely correlated [74]. All together, 
these data indicate that immune activation characterizes ESN 
individuals, suggesting that immunophenotypic profiles were 
a consequence of HIV-1 exposure or antigenic level. 
  Several reports indicate that cytotoxic T lymphocytes 
(CTL) play an important role in preventing HIV infection. 
The first demonstration of HIV-1-specific CD8+ lymphocyte 
responses in the cervix of ESNs was showed by Kaul et al; 
they demonstrated that CD8+ lymphocytes produced IFN- 
in response to HIV-1 [75]. As previously mentioned, the 
immune activation phenotype and the ability to produce IFN-
–appears to be important characteristics of CTLs from 
ESNs [72, 74], suggesting that exposure to HIV-1 influences 
the maturation profile of subsets of T lymphocytes that could 
be associated to HIV resistance. 
  In addition to the cytotoxic activity of CTLs, CD8+ T 
cells from ESNs have also shown strong noncytotoxic anti-
HIV responses, mediated by other soluble factors different 
than  -chemokines [49]. Additionally, Pallikkuth et al. 
reported higher intracellular levels of perforin and granzyme 
B expression in CD8+T cells after stimulation with gag p24 
antigen in ESNs compared to HCs [76]. 
CONCLUSIONS 
 CCR5  32 polymorphism remains the main genetic 
factor that confers resistance to HIV-1. However, phenotypic 
and functional characteristics of immune cells and the 
antiviral activity of soluble factors have become the aim of 
several studies trying to determine their association with 
protection against HIV infection. As described in this 
review, although some of these cells and molecules have 
been clearly associated with the phenomenon of natural 
resistance to HIV-1 infection, the mechanisms responsible 
for viral inhibition are not fully understood. A better 
understanding of this phenomenon is essential for the 
development of effective vaccines to prevent viral infection. 
In this sense, the groups of ESNs, ellite controllers and 
LTNPs will continue to be the main target populations to 
address the variety of mechanisms which allow controlling 
HIV infection. 
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